Prostate Cell News Volume 9.03 | Jan 26 2018

TOP STORY

Plumbagin Triggers ER Stress-Mediated Apoptosis in Prostate Cancer Cells via Induction of ROS

Researchers found that plumbagin (PLB) decreases cancer cell growth and induces apoptosis in DU145 and PC-3 cells. In addition, by increasing intracellular reactive oxygen species (ROS) levels, PLB induced a lethal endoplasmic reticulum stress response in prostate cancer cells. [Cell Physiol Biochem] Full Article

(Ranked by impact factor of the journal)

Targeted AKT Inhibition in Prostate Cancer Cells and Spheroids Reduces Aerobic Glycolysis and Generation of Hyperpolarized [1-¹³C] Lactate

Specific AKT inhibitors are now in advanced clinical trials and scientists investigated the effect of MK2206, a non-ATP competitive inhibitor, on the cellular metabolism in the context of prostate cancer. A significant reduction in cell motility and aerobic glycolysis was observed in prostate cancer cells with treatment. [Mol Cancer Res] Abstract | Full Article

Hyper-Acetylation Contributes to the Sensitivity of Chemo-Resistant Prostate Cancer Cells to Histone Deacetylase Inhibitor Trichostatin A

Screening assays demonstrated that chemotherapy-resistant prostate cancer (PCa) cells are more sensitive to histone deacetylase inhibitors than paired sensitive PCa cells, as demonstrated by cell proliferation and apoptosis in vitro and in vivo. [J Cell Mol Med] Abstract | Full Article

Regulation of UDP-Glucuronosyltransferase 2B15 by miR-331-5p in Prostate Cancer Cells Involves Canonical and Non-Canonical Target Sites

miR-331-5p mimics significantly reduced both UGT2B15 mRNA levels and glucuronidation activity in prostate cancer cells, confirming that the native transcript is a miR-331-5p target. [J Pharmacol Exp Ther] Abstract | Full Article

Matrine Inhibits the Progression of Prostate Cancer by Promoting Expression of GADD45B

Investigators analyzed KEGG pathways of differential gene expression between matrine-treated and untreated prostate cancer cell lines and identified GADD45B as one of the major target genes of matrine based on its role in apoptosis and prognosis value for prostate cancer patients in the TCGA database. [Prostate] Abstract

p62 as a Therapeutic Target for Inhibition of Autophagy in Prostate Cancer

Verteporfin inhibited cell growth and colony formation in PC-3 cells. Verteporfin generated crosslinked p62 oligomers, resulting in inhibition of autophagy and constitutive activation of Nrf2 as well as its target genes, Bcl-2 and TNF-α. [Prostate] Abstract

Activation of Estrogen Receptor Beta (ERβ) Regulates the Expression of N-Cadherin, E-Cadherin and β-Catenin in Androgen-Independent Prostate Cancer Cells

Researchers investigated the impact of the activation of estrogen receptors on expression and localization of N-cadherin, E-cadherin and non-phosphorylated β-catenin in androgen-independent prostate cancer cells and in human post pubertal prostate epithelial cells. [Int J Biochem Cell Biol] Abstract

FAM3B/PANDER Inhibits Cell Death and Increases Prostate Tumor Growth by Modulating the Expression of Bcl-2 and Bcl-XL Cell Survival Genes

FAM3B expression was analyzed by quantitative PCR in tumor tissue clinical samples and prostate tumor cell lines. Culture growth and viability of DU145 cell line were evaluated after treatment with either exogenous FAM3B protein obtained from conditioned media of 293 T cells overexpressing FAM3B or a recombinant FAM3B protein produced in a bacterial host. [BMC Cancer] Abstract | Full Article

Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells

Investigators showed that miR-133b was downregulated, while human antigen R (HuR) was upregulated in prostate cancer cells. HuR was identified as a target of miR-133b, and miR-133b could suppress HuR expression. [DNA Cell Biol] Abstract

CTC-Derived AR-V7 Detection as a Prognostic and Predictive Biomarker in Advanced Prostate Cancer

The authors review the available biomarkers in castration-resistant prostate cancer and discuss emerging data on the value of circulating tumor cell (CTC)-derived AR-V7 status to assess prognosis and its potential role to guide treatment selection for patients with advanced prostate cancer. [Expert Rev Mol Diagn] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers Including New Data on Apalutamide (ARN-509), ZYTIGA^® (Abiraterone Acetate) and Erdafitinib

New data from the Janssen Pharmaceutical Companies of Johnson & Johnson will be presented. In total, 14 company-sponsored abstracts with data for both investigational and approved compounds have been accepted for presentation, including for apalutamide and ZYTIGA^® in prostate cancer, and for erdafitinib in urothelial cancer. [Press release from Janssen Global Services, LLC discussing research to be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 Cancers Symposium, San Francisco] Press Release

The Prostate Cancer Foundation Awards Unprecedented Number of New Research Grants

The Prostate Cancer Foundation (PCF) announced it has awarded an additional $8 million in research funding to eight new 2017 PCF Challenge Award teams, bringing its total investment in 2017 to $27.8 million. [Prostate Cancer Foundation] Press Release

Trovagene Announces Initiation of UNITE Phase II Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trovagene, Inc. announced the initiation of its Phase II clinical trial evaluating the combination of PCM-075 and abiraterone acetate in patients with mCRPC. [Trovagene, Inc.] Press Release

Nymox Reports 5-Year Results from Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men

Nymox Pharmaceutical Corporation reported top-line five-year results from Nymox’s U.S. Study NX03-0040. Study NX03-0040 was undertaken starting in 2012 at 44 investigational sites across the U.S. comprising a highly representative sample of 146 men with the biopsy confirmed diagnosis of T1c prostate cancer. [Nymox Pharmaceutical Corporation] Press Release

Gender Bias Goes Away When Grant Reviewers Focus on the Science

But female scientists suffer when their research proposals are judged primarily on the strength of their CVs. [Nature News] Editorial

German Scientists Hope for Windfall from Incoming Government

Research budget could rise to 3.5% of gross domestic product if agreement struck during coalition talks holds. [Nature News] Editorial

Nobel Laureate Suggests He Could Fall on Sword over Colleague’s Bogus Paper

Shinya Yamanaka, who won a share of the 2012 Noble Prize in Physiology or Medicine for the discovery of induced pluripotent stem (iPS) cells, has suggested he could resign as director of Kyoto University’s Center for iPS Cell Research and Application in Japan over a fraudulent paper published by center researchers. [ScienceInsider] Editorial

NEW The Stem Cell Niche Conference 2018
May 27-31, 2018
Copenhagen, Denmark

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Cancer Biology (Wake Forest Baptist Comprehensive Cancer Center)

NEW Team Leader – Drug Discovery Biology (Institute of Cancer Research)

NEW PhD Scholarships – Human Health & Emerging Environmental Contaminants (University of Hull)

PhD Positions – Cancer Imaging (University of Hull)

Postdoctoral Position – Molecular Imaging and Radionuclide Therapy in Prostate Cancer (Klinikum rechts der Isar)

Professor, Tenure Canada Excellence Research Chair – Precision Cancer Drug Design (University of British Columbia)

Assistant Professor, Associate Professor & Professor – Cell & Molecular Biology (University of Mississippi)

Postdoctoral Positions – Gene Regulation and/or Cancer Biology (University of North Carolina)

Assistant/Associate Professor – Prostate Cancer (Northwestern University)

Postdoctoral Fellowship – Prostate Cancer (Duke University Medical Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.